The Growing Number of Viral and Bacterial Infections Supported by the Recent Pandemic Trends and Assistance in Other Ailments have been Providing the Necessary Impetus to the Antipyretics Market During the Forecast Period of 2022-2027.

Antipyretics Market Size is estimated to reach $3.1 billion by 2027 and it is poised to grow at a CAGR of 1.6% over the forecast period of 2022-2027. Antipyretics agents have been used for over millennia to suppress viral fever and fever from bacterial infections. The essential elements of the fever physiologic pathway are a release of pyrogenic cytokines by inflammatory cells in response to some exogenous pyrogen (infection) and induction of cyclooxygenase (COX) 2 activation of the arachidonic acid cascade. The common forms of antipyretics analgesics drugs include but are not limited to paracetamol, ibuprofen (NSAIDs), corticosteroids, acetaminophen (Tylenol) and others. The market for antipyretic drugs has been positively positioned owing to various research and development activities within the pharmaceutical world along with the growing disease burden pertinent to newer forms of infections. 

Antipyretic Market Drivers

The Rising Prevalence of Conditions Such as Flu, Headaches, Among Other Applicative Classes Drives the Market Forward.

Paracetamol or Acetaminophen is a common product prescribed to patients suffering from migraines or acute headaches. As per NCBI, nearly 1 in 7 Americans each year report migraine form of headache, thereby, reflecting nearly 40-45 million of the active population. Furthermore, seasonal flu drives the demand for the following drug class, as fever belongs to the most significant symptom of seasonal flu.  According to CDC, within the last flu season of 2022- around 4.7 million illnesses and 47,000 hospitalizations have taken place in the U.S.

For More Queries About "Antipyretic Market" @ https://www.industryarc.com/support.php?id=17706

The Support Provided by COVID-19 in Curating Heightened Demand Along with Product Awareness has Driven the Market.

As per Frontier.Org, fever tends to remain one of the typical symptoms of COVID-19. Based on a meta-analysis by researchers, fever as a symptom was present in nearly 85.6% of all COVID-19 cases during the course of the disease. Furthermore, medicines proliferated under the category of analgesics and antipyretics held a larger growth which pushed the market further. As per Nature 2021, nearly 26 randomized trials are underway for treating long-COVID. Of the candidates present, nearly 9 of the drugs are anti-inflammatory or antipyretics, which work on reducing aches and fever.

Product Launch and Innovation

In May 2022, Strides Pharma was granted approval for OTC Oral Suspension Ibuprofen for the sale in the region. The product manufacturing will be completed in Bengaluru, India. In January 2020, Cumberland Pharmaceuticals innovated and launched a newer form of injectable ibuprofen which proclaims to reduce the use of opioid painkillers in hospital settings.

The Major Players in the Market Include

The major players in the Antipyretics Market include Dr. Reddy Labs, CIPLA Ltd, Sun Pharmaceuticals, Glenmark Pharma, Pfizer, GSK Pharma, BASF, Novartis, LUPIN and Zydus Life.

Over the years, the major market players have introduced newer products in accordance with the nuanced laws for OTC push in the marketplace. Private labelers and generic classes of drugs continue to put cost pressures on the market players.